Skip to content

Not yet independently audited

This page was written from verified sources but has not yet passed the independent citation audit. Treat its claims as provisional.

Guidelines

TL;DR — No major society publishes a complete HHD-specific pathway from exposure through imaging, fibrosis, arrhythmia and HF. Instead, care is assembled from hypertension, HF, AF, secondary-hypertension and cardiomyopathy guidance. The current U.S. hypertension framework is the 2025 multisociety AHA/ACC guideline, which replaces 2017; Europe has distinct 2024 ESC and 2023 ESH documents (Jones 2025, PMID 40815242; McEvoy 2024, PMID 39210715; Mancia 2023, PMID 37345492). They differ in terminology, thresholds, target ranges and risk-based initiation. WHO and ISH emphasize feasible global implementation; NICE and Canadian guidance use their own measurement and primary-care frameworks (Al-Makki 2022, PMID 34775787; Unger 2020, PMID 32370572; Boffa 2019, PMID 31636059; Goupil 2025, PMID 40419299). Any target quoted in this wiki is therefore paired with its measurement protocol and source.

1. Guideline stack for HHD

Clinical question Governing guidance family
Diagnose and treat elevated BP Hypertension guideline
Evaluate target-organ damage Hypertension plus imaging guidance
Diagnose/treat HFpEF or HFrEF Heart-failure guideline
Manage AF/stroke prevention AF guideline
Evaluate disproportionate LVH HCM/infiltrative-disease guidance
Screen/treat PA Endocrine guideline
Manage emergency BP with organ injury Acute-care/hypertension guidance

The absence of a single document is not permission to merge recommendations without their populations and evidence grades.

2. Current major hypertension documents

Body/document Year Region Distinguishing feature Status
AHA/ACC multisociety 2025 United States Risk-based prevention; replaces 2017 document Current (Jones 2025, PMID 40815242)
ESC 2024 Europe “Elevated BP” category and treated systolic range 120–129 if tolerated Current (McEvoy 2024, PMID 39210715)
ESH 2023 Europe/international Separate society framework with graded targets and organ-damage emphasis Current (Mancia 2023, PMID 37345492)
ESH clinical practice 2024 Europe/international Concise practice implementation of 2023 framework Current (Kreutz 2024, PMID 38914505)
WHO 2021/2022 publication Global Pharmacologic treatment recommendations designed for broad implementation Current (Al-Makki 2022, PMID 34775787)
ISH 2020 Global Essential versus optimal standards for different-resource settings Current but older (Unger 2020, PMID 32370572)
NICE NG136 summary 2019, maintained online UK Clinic plus ABPM/HBPM confirmation and age-specific targets Current online maintenance required (Boffa 2019, PMID 31636059)
Hypertension Canada 2025 Canada Primary-care diagnostic/treatment guideline Current (Goupil 2025, PMID 40419299)

3. U.S. 2025 AHA/ACC

The 2025 guideline explicitly retires/replaces the 2017 multisociety document. It continues a cardiovascular-risk framework, emphasizes accurate measurement, out-of-office confirmation/monitoring, lifestyle and earlier treatment for higher-risk adults (Jones 2025, PMID 40815242).

HHD implications:

  • LVH, HF, CKD and established CVD affect absolute risk and therapeutic context.
  • A clinic label alone is insufficient when white-coat or masked hypertension is plausible.
  • The target framework should not be back-projected onto casual unstandardized readings.
  • Existing HF or AF invokes separate disease-specific recommendations.

Reviews of the 2025 update emphasize continuity and changes from the prior framework; they are interpretive sources, not substitutes for the guideline (Brown 2026, PMID 41843050).

4. 2024 ESC versus 2023 ESH

The 2024 ESC document introduced an “elevated BP” category and a general on-treatment systolic target range of 120–129 mm Hg when tolerated, with exceptions based on symptoms, frailty and clinical context (McEvoy 2024, PMID 39210715; Cohen 2025, PMID 39284002).

The 2023 ESH guideline uses its own classification, initiation and age/tolerance framework, and retains extensive target-organ-damage evaluation (Mancia 2023, PMID 37345492).

Issue ESC 2024 ESH 2023 HHD consequence
Nomenclature below hypertension “Elevated BP” Different graded classification Prevalence labels differ
Treated systolic emphasis 120–129 if tolerated for many Stepwise/age-context target structure Quote source and tolerance rule
Risk assessment Integrated CVD risk Integrated risk/organ damage HHD raises risk but is not uniformly defined
Out-of-office BP Central Central Measurement thresholds differ from clinic
Frailty/older age Individualize Individualize Avoid numeric-only interpretation

Contemporary comparison papers explicitly document these differences (Wang 2025, PMID 39997480; Burlacu 2025, PMID 40005310; McCarthy 2025, PMID 39970254).

5. WHO and ISH implementation focus

WHO pharmacologic guidance prioritizes treatment initiation, drug classes, combination therapy, follow-up and team-based delivery in a form usable across resource settings (Al-Makki 2022, PMID 34775787).

ISH 2020 deliberately separates “essential” standards feasible in low-resource settings from “optimal” standards, a design relevant where ABPM, biomarkers and CMR are unavailable (Unger 2020, PMID 32370572).

PASCAR commentary examined the ISH framework’s relevance to sub-Saharan Africa, where workforce, access and medication availability constrain implementation more than marginal threshold differences (Jones 2020, PMID 33404583).

6. NICE and Canada

NICE uses ABPM to confirm diagnosis when clinic BP is elevated, with HBPM when ABPM is unsuitable, and retains age-specific clinic/home target conventions (Boffa 2019, PMID 31636059).

Hypertension Canada’s 2025 primary-care guideline updates diagnosis and treatment for Canadian practice; repeated records/publications should be treated as manifestations of one document, not independent guidelines (Goupil 2025, PMID 40419299; Goupil 2025, PMID 40527605).

The practical lesson is that “controlled” must be defined by guideline, setting and measurement.

7. Target-organ damage and imaging

Question Broad guideline consensus Persistent disagreement/gap
ECG in initial evaluation Widely available and prognostic Low sensitivity for anatomical LVH
Echo Useful when organ damage or cardiac disease suspected Whether universal screening is cost-effective
CMR Valuable for uncertain phenotype/differential No routine population screening mandate
Serial imaging Reasonable when findings/management change No validated HHD-specific interval
Biomarkers Useful in HF/risk contexts No universal asymptomatic HHD stage trigger

The literature recommends multimodality imaging for selected HHD evaluation, but guideline implementation is limited by availability and absence of outcome trials for screening (Ismail 2023, PMID 37176563; Tadic 2021, PMID 32170529).

8. Heart-failure guidance

The 2022 AHA/ACC/HFSA and 2021 ESC HF guidelines define HF stages/categories and syndrome-specific therapy (Heidenreich 2022, PMID 35363499; McDonagh 2021, PMID 34447992).

HF phenotype Guideline-relevant HHD principle
Pre-HF Structural disease/biomarker injury without symptoms; prevention opportunity
HFrEF Foundational outcome-modifying therapy irrespective of hypertension attribution
HFmrEF Evidence partly extrapolated/across EF spectrum
HFpEF Confirm syndrome, decongest, control BP/comorbidities, use current outcome evidence

Neither guideline establishes CMR fibrosis regression as a treatment target in asymptomatic HHD.

Superseded on 2026-08-28. The ESC released the 2026 ESC Guidelines for the management of heart failure, which replace the 2021 document as the European HF anchor, and — alongside it — the 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, produced with the European Renal Association (Køber 2026, PMID 42661420; Damman 2026, PMID 42661426). This sweep verified that both records exist and are indexed but did not obtain the guideline texts, so no recommendation, class, level of evidence or threshold from either document is asserted anywhere in this wiki. Sections 8 and 11 below, the HFpEF/HFrEF rows above and every statement sourced to McDonagh 2021 (PMID 34447992) therefore still describe the 2021 document and must be re-synthesized against the 2026 text before they can be treated as current. Two questions matter most for HHD when the text is read: whether the pre-HF (stage B) definition now incorporates imaging or biomarker criteria, and whether the CKD guideline changes the BP target or RAAS/MRA safety boundaries that constrain HHD treatment in reduced eGFR.

9. AF guidance

The 2023 ACC/AHA/ACCP/HRS AF guideline addresses detection, stroke prevention, rate/rhythm control and risk-factor modification (Joglar 2024, PMID 38033089; Writing Committee 2024, PMID 38043043).

HHD/LVH affects substrate and risk but does not create anticoagulation without documented AF or an ICD indication without conventional ventricular-arrhythmia criteria.

10. Primary aldosteronism guidance

The 2025 Endocrine Society PA guideline updates screening, confirmation, subtype evaluation and treatment (Adler 2025, PMID 40658480). This is central to disproportionate HHD because PA is associated with excess LVH, AF, HF and stroke (Monticone 2018, PMID 29129575).

11. Regional implementation and gaps

South African implementation research documents the distance between guideline existence and achieved control in routine services (Ditlhabolo 2024, PMID 39494661). A systematic review found important content and implementation gaps between lower- and higher-income-country hypertension guidelines (Owolabi 2016, PMID 27698059).

Implementation domain Metric that matters
Detection Proportion measured with valid devices/protocol
Confirmation Access to repeat/home/ambulatory measurement
Treatment Affordable continuous medication supply
Control Standardized BP distribution, not documentation alone
HHD detection Risk-based access to ECG/echo
Follow-up Retention, titration and laboratory safety

12. Guideline-discordance rules for this wiki

  1. Name the body and year.
  2. State measurement setting.
  3. Separate diagnostic threshold from treatment target.
  4. Preserve “if tolerated,” frailty and comorbidity qualifiers.
  5. Do not average conflicting thresholds.
  6. Prefer current documents and retain superseded chains in the registry.
  7. Distinguish recommendation from randomized effect estimate.

Open questions

  • Should HHD imaging or biomarkers formally alter treatment initiation/intensity beyond clinical CVD risk? (Sharp 2026, PMID 41771092)
  • Can one minimum global HHD phenotype be feasible across essential and optimal resource standards? (Unger 2020, PMID 32370572; Ismail 2023, PMID 37176563)
  • Which apparent U.S.–European target differences persist after harmonizing measurement technique and tolerability? (Jones 2025, PMID 40815242; McEvoy 2024, PMID 39210715)
  • How should implementation success be measured where ABPM, echo and stable medication supply are limited? (Jones 2020, PMID 33404583; Ditlhabolo 2024, PMID 39494661)
  • Do the 2026 ESC heart-failure and CKD guidelines change the pre-HF definition or the BP/RAAS boundaries relevant to HHD? (Køber 2026, PMID 42661420; Damman 2026, PMID 42661426)

References

  1. Jones DW, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;86:1567-1678. PMID 40815242
  2. McEvoy JW, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912-4018. PMID 39210715
  3. Mancia G, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41:1874-2071. PMID 37345492
  4. Kreutz R, et al. 2024 European Society of Hypertension clinical practice guidelines for the management of arterial hypertension. Eur J Intern Med. 2024;126:1-15. PMID 38914505
  5. Al-Makki A, et al. Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary. Hypertension. 2022;79:293-301. PMID 34775787
  6. Unger T, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334-1357. PMID 32370572
  7. Boffa RJ, et al. Hypertension in adults: summary of updated NICE guidance. BMJ. 2019;367:l5310. PMID 31636059
  8. Goupil R, et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. CMAJ. 2025;197:E549-E564. PMID 40419299
  9. Brown C, et al. Updates in the 2025 AHA/ACC Hypertension Guideline. Curr Hypertens Rep. 2026;28. PMID 41843050
  10. Cohen JB. What Is New in the ESC Hypertension Guideline? Hypertension. 2025;82:11-13. PMID 39284002
  11. Wang BX. Diagnosis and Management of Hypertensive Heart Disease: Incorporating 2023 European Society of Hypertension and 2024 European Society of Cardiology Guideline Updates. J Cardiovasc Dev Dis. 2025;12. PMID 39997480
  12. Burlacu A, et al. Key Updates to the 2024 ESC Hypertension Guidelines and Future Perspectives. Medicina (Kaunas). 2025;61. PMID 40005310
  13. McCarthy CP, et al. What Is New and Different in the 2024 European Society of Cardiology Guidelines for the Management of Elevated Blood Pressure and Hypertension? Hypertension. 2025;82:432-444. PMID 39970254
  14. Jones ES, et al. PASCAR commentary on the International Society of Hypertension global guidelines 2020: relevance to sub-Saharan Africa. Cardiovasc J Afr. 2020;31:325-329. PMID 33404583
  15. Goupil R, et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. Can Fam Physician. 2025;71:467-482. PMID 40527605
  16. Ismail TF, et al. Hypertensive Heart Disease-The Imaging Perspective. J Clin Med. 2023;12. PMID 37176563
  17. Tadic M, et al. Comprehensive assessment of hypertensive heart disease: cardiac magnetic resonance in focus. Heart Fail Rev. 2021;26:1383-1390. PMID 32170529
  18. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895-e1032. PMID 35363499
  19. McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-3726. PMID 34447992
  20. Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149:e1-e156. PMID 38033089
  21. Writing Committee Members. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024;83:109-279. PMID 38043043
  22. Adler GK, et al. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2025;110:2453-2495. PMID 40658480
  23. Monticone S, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41-50. PMID 29129575
  24. Ditlhabolo KI, et al. Hypertension guideline implementation and blood pressure control in Matlosana, South Africa. S Afr Fam Pract (2004). 2024;66:e1-e10. PMID 39494661
  25. Owolabi M, et al. Gaps in Hypertension Guidelines in Low- and Middle-Income Versus High-Income Countries: A Systematic Review. Hypertension. 2016;68:1328-1337. PMID 27698059
  26. Sharp A, et al. Role of natriuretic peptides and cardiac troponins in staging hypertensive heart disease: the REMODEL study. Eur J Heart Fail. 2026. PMID 41771092
  27. Køber L, et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. 2026;:ehag100. PMID 42661420
  28. Damman K, et al. 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA). Eur Heart J. 2026;:ehag098. PMID 42661426